FilippiMPreziosaPCopettiM, et al. Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology2013; 81(20): 1759–1767.
2.
RoccaMAValsasinaPMeaniA, et al. Association of gray matter atrophy patterns with clinical phenotype and progression in multiple sclerosis. Neurology2021; 96(11): e1561–e1573.
3.
GiovannoniGSoelberg SorensenPCookS, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler2018; 24(12): 1594–1604.
4.
CorteseRBattagliniMSormaniMP, et al. Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets. Eur J Neurol2023; 30(1): 179–186.
5.
GiovannoniGKnappertzVSteinermanJR, et al. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology2020; 95(8): e1027–e1040.
6.
Barrantes-CepasMNoteboomSColatoE, et al. Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis. Mult Scler2025; 31(6): 696–705.
7.
AchironAWarszawerYNissanY, et al. Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study. Mult Scler2025; 31(6): 689–695.
8.
EshaghiAPradosFBrownleeWJ, et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol2018; 83(2): 210–222.
9.
BattagliniMJenkinsonMDe StefanoN. Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp2012; 33(9): 2062–2071.
10.
PradosFCardosoMJKanberB, et al. A multi-time-point modality-agnostic patch-based method for lesion filling in multiple sclerosis. Neuroimage2016; 139: 376–384.
